Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
regulatory affairs
Biotech
82% of industry CEOs concerned about FDA's abilities: survey
Biotech CEOs worry that added volatility in an already high-risk industry will discourage investment or will drive it to other countries.
Gabrielle Masson
Nov 21, 2025 4:38pm
'Clinical intuition' led FDA advisors to back Zevra's rare disease med
Aug 5, 2024 10:35am
Takeda takes $140M loss on failed epilepsy drug, touts FDA run
Jul 31, 2024 9:14am
Allarity warned of pending SEC charges over FDA meeting conduct
Jul 22, 2024 9:50am
Insmed's shares double as lung disease med powers past phase 3
May 28, 2024 10:32am
Larimar's Friedreich's ataxia program free at last from FDA hold
May 21, 2024 9:55am
